Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 14/20 | 0.51 |
| ▸ | CA2 | P00918 | 13/20 | 0.51 |
| ▸ | CA12 | O43570 | 9/20 | 0.51 |
| ▸ | CA1 | P00915 | 9/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8469388 | 0.90 | SCN5A (0.46) | CA9CA2CA12CA1DPP4 | |
| SCHEMBL8472388 | 0.86 | DPP4 (0.55) | DPP4SCN5ASCN10A | |
| SCHEMBL4891043 | 0.78 | CA9 (0.49) | CA9CA2CA12CA1S1PR1 | |
| SCHEMBL4891054 | 0.78 | CA9 (0.49) | CA9CA2CA12CA1S1PR1 | |
| SCHEMBL4888547 | 0.78 | CTSS (0.42) | CA9CA2CA12CA1S1PR1 | |
| SCHEMBL4888639 | 0.76 | SCN5A (0.47) | DPP4SCN5ASCN10A | |
| SCHEMBL8471794 | 0.74 | NPC1 (0.60) | DPP4 | |
| SCHEMBL5178277 | 0.72 | NPSR1 (0.43) | — | |
| SCHEMBL4884701 | 0.71 | SMN1; SMN2 (0.41) | CA9CA2CA12CA1DPP4 | |
| SCHEMBL4888552 | 0.71 | CA2 (0.39) | CA9CA2CA12CA1S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064728-A1 | Heterocyclic Compounds Useful as Dpp-Iv Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2008-03-13 | — | — | US | disclosed |
| US-20080064728-A1 | Heterocyclic Compounds Useful as Dpp-Iv Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2008-03-13 | — | — | US | disclosed |
| US-20080064728-A1 | Heterocyclic Compounds Useful as Dpp-Iv Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2008-03-13 | — | — | US | disclosed |
| EP-1623983-A1 | Heterocyclic compounds useful as DPP-IV inhibitors | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft (DE) | 2006-02-08 | — | — | EP | disclosed |
| EP-1623983-A1 | Heterocyclic compounds useful as DPP-IV inhibitors | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft (DE) | 2006-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064728-A1 | Heterocyclic Compounds Useful as Dpp-Iv Inhibitors | DPP4, DPP7, DPP3 | CA9 429/4885CA2 513/4885CA12 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.